InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,554.25
(
0.20%
)
US TECH 100
18,971.20
(
-0.03%
)
Dow Jones
40,659.76
(
0.24%
)
Brent Oil
79.14
(
0.38%
)
Bitcoin
58,503.38
(
0.08%
)
Post# of 252904
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

stockbettor

Send PM Follow Ignore
Followers 3
Posts 278
Boards Moderated 0
Alias Born 03/08/2008

stockbettor

Re: Regulardoc post# 118640

Thursday, 04/21/2011 11:06:36 AM

Thursday, April 21, 2011 11:06:36 AM

Post# of 252904
Seems to me the more consequential trial will be the second P3 Biogen is running, which includes a Copaxone arm:

In addition to DEFINE, another Phase 3 RRMS clinical trial, CONFIRM, is currently underway. This study is evaluating BG-12 and an active reference comparator, glatiramer acetate, against placebo on clinical relapse, magnetic resonance imaging (MRI) measures of MS, progression of disability, and safety. Results from CONFIRM are expected in the second half of 2011.



http://www.biogenidec.com/PRESS_RELEASE_DETAILS.aspx?ID=5981&ReqId=1548648

http://clinicaltrials.gov/ct2/show/NCT00451451

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up